Patents by Inventor Remy Pujol

Remy Pujol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10966940
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: April 6, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Auris Medical AG
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Publication number: 20180256514
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Application
    Filed: November 15, 2017
    Publication date: September 13, 2018
    Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
  • Patent number: 10001082
    Abstract: An assembly for a turbojet engine includes a pylon, a nacelle supported by the pylon, and a locking device interposed between the pylon and a cowl of the nacelle. The cowl slides between operating and maintenance positions. The locking device is movable between active and inhibited positions, and the device allows an operation mode in the active position and a maintenance mode in the inhibited position. In particular, the locking device comprises a rocker to maintain the cowl to the pylon, and the rocker includes an inhibiting lever and an activation lever. The inhibiting and activation levers are mounted on a switching shaft of the locking device. The inhibiting lever is set in rotation through an actuator, providing direct access from a bypass flow duct in the active position while the activation lever is set in rotation from the bypass duct in the inhibited position.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: June 19, 2018
    Assignee: AIRCELLE
    Inventors: Olivier Conet, Rémi Pujol, Michel Jean, Jean-Francois Thouement
  • Publication number: 20170224638
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Application
    Filed: September 7, 2016
    Publication date: August 10, 2017
    Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
  • Patent number: 9463168
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: October 11, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), AURIS MEDICAL AG
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Publication number: 20150292436
    Abstract: An assembly for a turbojet engine includes a pylon, a nacelle supported by the pylon, and a locking device interposed between the pylon and a cowl of the nacelle. The cowl slides between operating and maintenance positions. The locking device is movable between active and inhibited positions, and the device allows an operation mode in the active position and a maintenance mode in the inhibited position. In particular, the locking device comprises a rocker to maintain the cowl to the pylon, and the rocker includes an inhibiting lever and an activation lever. The inhibiting and activation levers are mounted on a switching shaft of the locking device. The inhibiting lever is set in rotation through an actuator, providing direct access from a bypass flow duct in the active position while the activation lever is set in rotation from the bypass duct in the inhibited position.
    Type: Application
    Filed: December 4, 2014
    Publication date: October 15, 2015
    Inventors: Olivier CONET, Rémi PUJOL, Michel JEAN, Jean-Francois THOUEMENT
  • Publication number: 20150265552
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Application
    Filed: June 2, 2015
    Publication date: September 24, 2015
    Inventors: GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
  • Patent number: 9072662
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: July 7, 2015
    Assignees: Auris Medical AG, Institut National De La Sante et de La Recherche Medicale
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Publication number: 20150057360
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 26, 2015
    Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
  • Publication number: 20140017172
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Application
    Filed: July 9, 2013
    Publication date: January 16, 2014
    Inventors: Matthieu GUITTON, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Patent number: 8507525
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: August 13, 2013
    Assignee: Auris Medical AG
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Patent number: 8268866
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, sudden deafness, or other cochlear excitotoxic-inducing occurrence.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: September 18, 2012
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol
  • Publication number: 20100254907
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Application
    Filed: April 1, 2010
    Publication date: October 7, 2010
    Inventors: Matthieu GUITTON, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Publication number: 20100173874
    Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.
    Type: Application
    Filed: July 30, 2009
    Publication date: July 8, 2010
    Inventors: Jean-Luc Puel, Remy Pujol, Yves Christen
  • Patent number: 7589110
    Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: September 15, 2009
    Assignees: Durect Corporation, Inserm
    Inventors: Jean-Luc Puel, Remy Pujol, Yves Christen
  • Publication number: 20070015727
    Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.
    Type: Application
    Filed: September 6, 2002
    Publication date: January 18, 2007
    Inventors: Jean-Luc Puel, Remy Pujol, Yves Christen
  • Publication number: 20060063802
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Application
    Filed: September 28, 2005
    Publication date: March 23, 2006
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Publication number: 20050214338
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, sudden deafness, or other cochlear excitotoxic-inducing occurrence.
    Type: Application
    Filed: March 29, 2004
    Publication date: September 29, 2005
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol